• Users Online: 357
  • Print this page
  • Email this page
Ahead of Print

Cyclosporine 0.1% (Ikervis®) as a corticoid-sparing agent in lyell syndrome with keraklear® keratoprosthesis

 Department of Ophthalmology, Hospital Universitari i Politecnic La Fe, Valencia, Spain

Correspondence Address:
Miriam Rahhal-Ortuno,
Calle Hebreísta Pérez Bayer 11, 6-A; Valencia, Postal Code 46002
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/tjo.tjo_1_20

Cyclosporine 0.1% was used in a patient with Lyell syndrome, which had undergone a KeraKlear® keratoprosthesis implant due to the severe ocular involvement to avoid overuse of corticoid agents. To the best of our knowledge, this is the first reported case of cyclosporine 0.1% eye drops to use in Lyell syndrome previously treated with keratoprosthesis implant.

Print this article
  Search Pubmed for
    -  Rahhal-Ortuno M
    -  Fernández-Santodomingo AS
    -  Villena-Alvarado C
    -  Marín-Payá E
    -  Aguilar-González M
    -  García-Delpech S
 Citation Manager
 Article Access Statistics
 Reader Comments
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded9    

Recommend this journal